GR1603 / Zhixiang (Shanghai) Pharma - LARVOL DELTA

Tolerability, safety, and pharmacokinetics of GR1603 injection in healthy subjects: a randomized, double-blind, placebo-controlled single-dose escalation clinical trial. (PubMed, Expert Opin Investig Drugs) - "The degrees of IFN gene signature were significantly inhibited in the higher dose groups. The safety/tolerability, PK and exploratory metrics observed in this study support further clinical development of GR1603."

Clinical • Journal • PK/PD data • Infectious Disease • Respiratory Diseases • IFNAR2

Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE (clinicaltrials.gov) - P1/2 | N=136 | Active, not recruiting | Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus